Calcium supplementation and ototoxicity in patients receiving cisplatin

Grau, Juan J.; Estapé, J.; Cuchi, M. A.; Fírvida, J. L.; Blanch, José Luís; Ascaso, Carlos

doi:10.1046/j.1365-2125.1996.39114.x

Cited by 17 publications

(5 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, most of those studies were performed in children and a Cochrane systematic review concluded that the evidence was insufficient to allow for recommendation of such preventative treatments [24] . Similarly, our group has previously studied the effect on ototoxicity of maintaining serum calcium concentrations via calcium gluconate infusion in HNC patients treated with highdose cisplatin, but we did not observe any protection against ototoxicity using this treatment [25] . Therefore in our opinion, while novel preventative treatments should continue to be sought, in the meanwhile, switching to less ototoxic treatment regimens, such as carboplatin or cetuximab, is a useful option.…”

Section: Discussionmentioning

confidence: 89%

The Role of Audiometry prior to High-Dose Cisplatin in Patients with Head and Neck Cancer

Caballero¹,

Mackers²,

Reig

et al. 2017

Oncology

Self Cite

View full text Add to dashboard Cite

Objectives: To analyze the role of audiometry in considering change to a less ototoxic treatment in head and neck cancer (HNC) patients. Methods: Consecutive patients prescribed high-dose cisplatin (100 mg/m²) between January 2013 and February 2015 were enrolled. Audiometry was performed at baseline and before cisplatin. Change to a less ototoxic agent or reduced cisplatin dose was considered with audiometric decreases >25 dB. Results: A total of 103 patients were included; the median age of the patients was 59 years (range 18−75). Cisplatin was intended curative (58%), adjuvant (32%), or palliative (10%). Forty-two participants (41%) did not commence high-dose cisplatin because of baseline audiometric alterations. Of 61 patients treated with high-dose cisplatin, 40 (66%) showed marked ototoxicity at the end of treatment. The mean hearing loss between initial and final audiometries showed a hearing loss at 4 and 8 kHz in both ears (p = 0.002). Thirteen patients switched to carboplatin and 15 to a lower dose of cisplatin. The outcome was not significantly altered when cisplatin was replaced with carboplatin or cetuximab. Conclusions: Audiometric alterations are common in HNC with high-dose cisplatin, and switching to a less ototoxic regimen does not adversely affect outcome. Audiometric examination could help to prevent hearing loss in this population.

show abstract

Section: Discussionmentioning

confidence: 89%

The Role of Audiometry prior to High-Dose Cisplatin in Patients with Head and Neck Cancer

Caballero¹,

Mackers²,

Reig

et al. 2017

Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Although not statistically significant, the combined cisplatinclotrimazole treatment of rats with 9L gliomas resulted in an additional survival benefit over the survival of rats treated with either drug alone. 17 When released from intracellular stores, but not moved from extracellular space, Ca ϩϩ plays a role in cisplatin-induced cell injury. The results of in vitro experiments do not always correspond to results that are obtained in vivo.…”

Section: Discussionmentioning

confidence: 99%

Inhibition of tumor growth and prolonged survival of rats with intracranial gliomas following administration of clotrimazole

Mh¹,

Tokunaga²,

Aj³

et al. 2005

Journal of Neurosurgery

View full text Add to dashboard Cite

show abstract

“…Mucositis is a dose-limiting toxicity in the first regimen and pulmonary toxicity in the second. Carboplatin has been used for selected patients due to its improved toxic profile compared with cisplatin especially as regards nephrotoxicity and ototoxicity [9]. Clinical series in general combine results of cancer in the oral cavity with cancer of the larynx or hypopharynx.…”

Section: Introductionmentioning

confidence: 99%

Multidisciplinary Approach in Advanced Cancer of the Oral Cavity: Outcome with Neoadjuvant Chemotherapy according to Intention-to-Treat Local Therapy

et al. 2002

Self Cite

View full text Add to dashboard Cite

Objectives: To determine outcomes in local-regional control and overall survival in patients with squamous locally advanced cancer of the oral cavity, based on intention-to-treat with neoadjuvant chemotherapy followed by surgery or radiation therapy. Methods: Two hundred and four out of 1,089 patients analyzed met the defined criteria. All had squamous cell carcinomas of the oral cavity in stage III or in nonmetastatic stage IV and were selected for surgery or radiation therapy (if located in the tonsils or in the base of the tongue). Chemotherapy was based on cisplatin 120 mg/m² i.v. day 1 plus bleomycin 20 mg/m² days 1–5 in continuous i.v. perfusion or plus 5-fluorouracil 1,000 mg/m² days 1–5 in continuous i.v. perfusion. A total of 418 cycles were given to 204 patients (mean 2.049 per patient). Definitive surgery (n = 73; plus adjuvant radiation therapy) or definitive radiation therapy (n = 131) was performed. Results: One hundred thirty-five out of 204 (66%) patients were chemotherapy responders, 16% complete and 50% partial. One hundred ninety-four patients (95%) completed 2 courses of chemotherapy. After neoadjuvant chemotherapy, 34 out of 46 patients considered inoperable initially (74%) obtained a disease-free status with surgery. Eighty-three percent of surgical patients obtained a disease-free status (initial tumor control) versus 72% of radiation therapy patients. Disease-free survival rates at 5 years were 26 and 22%, respectively. A better prognosis was observed in stage III over IV (p = 0.02); primary tumor in the retromolar trigone, palate or buccal mucosa over tongue, tonsil or floor of the mouth (p = 0.0085); negative cervical nodes over positive (p = 0.0186); responders to chemotherapy over nonresponders (p = 0.0003); and adjuvant postsurgical radiation therapy (p = 0.0013). Causes of death were relapses in local area (86%), regional nodes (10.5%) or distant metastases (3.5%). Eleven patients (5%) died of a second primary. The main toxic effects were vomiting in 9% of patients and hemolytic-uremic syndrome in 3% of the patients treated with bleomycin. Conclusions: In locally advanced squamous cell carcinoma of the oral cavity, neoadjuvant chemotherapy induces a high response rate that may facilitate definitive surgery or radiotherapy. In this study, patients have an acceptable long-term survival.

show abstract

Calcium supplementation and ototoxicity in patients receiving cisplatin

Cited by 17 publications

References 2 publications

The Role of Audiometry prior to High-Dose Cisplatin in Patients with Head and Neck Cancer

The Role of Audiometry prior to High-Dose Cisplatin in Patients with Head and Neck Cancer

Inhibition of tumor growth and prolonged survival of rats with intracranial gliomas following administration of clotrimazole

Multidisciplinary Approach in Advanced Cancer of the Oral Cavity: Outcome with Neoadjuvant Chemotherapy according to Intention-to-Treat Local Therapy

Contact Info

Product

Resources

About